Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1.
Giraud J, Chalopin D, Ramel E, Boyer T, Zouine A, Derieppe MA, Larmonier N, Adotevi O, Le Bail B, Blanc JF, Laurent C, Chiche L, Derive M, Nikolski M, Saleh M. Giraud J, et al. Among authors: adotevi o. Cell Rep. 2024 Feb 27;43(2):113773. doi: 10.1016/j.celrep.2024.113773. Epub 2024 Feb 12. Cell Rep. 2024. PMID: 38350444 Free article.
PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.
Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre JR, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron PF, Borg C, Hervouet E. Asgarova A, et al. Among authors: adotevi o. Oncoimmunology. 2018 Feb 1;7(5):e1423170. doi: 10.1080/2162402X.2017.1423170. eCollection 2018. Oncoimmunology. 2018. PMID: 29721376 Free PMC article.
The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S, Ricciardi-Castagnoli P, Goud B, Fridman WH, Johannes L, Tartour E. Haicheur N, et al. Among authors: adotevi o. J Immunol. 2000 Sep 15;165(6):3301-8. doi: 10.4049/jimmunol.165.6.3301. J Immunol. 2000. PMID: 10975847
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N. Simon S, et al. Among authors: adotevi o. J Immunother Cancer. 2020 Nov;8(2):e001631. doi: 10.1136/jitc-2020-001631. J Immunother Cancer. 2020. PMID: 33188038 Free PMC article.
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E. Bercovici N, et al. Among authors: adotevi o. J Immunother. 2008 Jan;31(1):101-12. doi: 10.1097/CJI.0b013e318159f5ba. J Immunother. 2008. PMID: 18157017 Clinical Trial.
Chemotherapy to potentiate the radiation-induced immune response.
Lecoester B, Wespiser M, Marguier A, Mirjolet C, Boustani J, Adotévi O. Lecoester B, et al. Among authors: adotevi o. Int Rev Cell Mol Biol. 2023;376:143-173. doi: 10.1016/bs.ircmb.2023.01.004. Epub 2023 Feb 11. Int Rev Cell Mol Biol. 2023. PMID: 36997268 Review.
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy.
Ben Khelil M, Godet Y, Abdeljaoued S, Borg C, Adotévi O, Loyon R. Ben Khelil M, et al. Among authors: adotevi o. Cancers (Basel). 2022 Jan 5;14(1):260. doi: 10.3390/cancers14010260. Cancers (Basel). 2022. PMID: 35008422 Free PMC article. Review.
109 results